Morphic Holding, Inc. (MORF)
| Market Cap | 931.57M |
| Revenue (ttm) | 38.71M |
| Net Income (ttm) | -47.08M |
| Shares Out | 30.53M |
| EPS (ttm) | -1.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $29.59 |
| Previous Close | $29.93 |
| Change ($) | -0.34 |
| Change (%) | -1.14% |
| Day's Open | 30.05 |
| Day's Range | 29.34 - 30.40 |
| Day's Volume | 16,557 |
| 52-Week Range | 10.84 - 34.55 |
New program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets New program demonstrates breadth of MInT platform with the inclusion of a...
The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sus...
WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., ...
As of late, it has definitely been a great time to be an investor in Morphic Holding (MORF).
WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the trea...
Initiated p hase 1 clinical trial for MORF-057 with results expected by mid-2021
- Data validat e physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α 4 β 7 integrin - -MORF-057, inhibitor of α 4 β 7 integrin, in development to...
First o rally available integrin inhibitor from MInT Platform to enter the clinic MORF-057, inhibitor o f α 4 β 7 integrin , in development to treat i nflammatory bowel disease ...
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the t...
WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...
AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 13.33% and 37.38%, respectively, for the quarter ended June 2020.
Company’s first IND accepted by FDA for MORF-057 in IBD Phase 1 study expected to begin in third-quarter 2020 Positive data presented at DDW 2020 further support MORF-057 preclinical profile
Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD
WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the ...
WALTHAM, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...
Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate
Morphic Holding Inc. (NASDAQ:MORF) is one of five fledgling biotechnology companies cited for their potential to develop a drug that generates more than $1 billion in sales, according to an ar...
WALTHAM, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of ...
Morphic Holding, Inc. (NASDAQ: MORF) made its public debut Thursday morning, opening at $18 after being priced at $15 per share.
About MORF
Morphic Holding, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral avß6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4ß7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD). The company i... [Read more...]
| Industry Biotechnology | IPO Date Jun 27, 2019 |
| CEO Dr. Praveen P. Tipirneni M.D. | Employees 87 |
| Stock Exchange NASDAQ | Ticker Symbol MORF |
Financial Performance
In 2019, MORF's revenue was $16.98 million, an increase of 405.57% compared to the previous year's $3.36 million. Losses were -$43.33 million, 81.8% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for MORF stock is "Strong Buy." The 12-month stock price forecast is 41.25, which is an increase of 39.41% from the latest price.